Stockreport

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Foghorn Therapeutics Inc.  (FHTX) 
PDF WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicin [Read more]